Despite the promising potential of STAT3 inhibitors, there are several challenges to their development and clinical use:
Specificity: Achieving selective inhibition of STAT3 without affecting other STAT proteins or signaling pathways is challenging. Toxicity: Inhibitors may exhibit off-target effects, leading to toxicity and adverse side effects. Delivery: Efficiently delivering these inhibitors to tumor cells while minimizing systemic exposure remains a significant hurdle.
